Bone Density and Muscle Loss on GLP-1s: The Evidence, and How to Protect Both

The short version

When you lose weight on a GLP-1, you don't only lose fat. Across the randomized trials, roughly a quarter to a third of the total weight lost is lean mass — muscle and other non-fat tissue — and that proportion is broadly similar whether the weight comes off with a GLP-1 or with diet and exercise alone¹. Separately, rapid or sustained weight loss of any kind is a recognized risk factor for lower bone mineral density, degraded bone microarchitecture, and higher fracture risk³. Neither of these is a reason to avoid treatment — but both are reasons to treat muscle and bone as things you actively defend, not bystanders. This matters in particular for women approaching and past menopause, when bone is already under pressure.

How much of GLP-1 weight loss is lean mass

The cleanest number comes from a 2026 systematic review of 20 randomized trials (15,782 participants) that measured body composition. Lean mass made up 25–39% of total weight lost with incretin drugs: about 35% with semaglutide, 25% with tirzepatide, and 27% with liraglutide¹. Crucially, lifestyle-only weight loss showed a comparable proportion (about 26%), meaning the lean-mass loss is largely a feature of losing weight itself, not something unique to the drugs¹.

A dedicated DXA substudy of the SURMOUNT-1 tirzepatide trial — a group that was 73% female — put concrete measurements on it: over 72 weeks, participants lost about 21% of body weight, of which roughly 75% was fat mass and 25% was lean mass². For context on the magnitude of weight change involved, semaglutide produced about 15% average weight loss in its pivotal obesity trial⁵ and tirzepatide about 20% at the top dose⁶ — so a "25% lean" share is a substantial absolute amount of tissue.

Why the bone question deserves attention

Weight-bearing tissue and the skeleton are linked: carrying less weight reduces mechanical load on bone, and aggressive calorie restriction changes the hormonal and nutritional signals that maintain it. A 2025 mechanistic review concluded that while moderate weight reduction can be metabolically beneficial, rapid or sustained weight loss is frequently associated with decreased bone mineral density, deterioration of bone microarchitecture, and heightened fracture risk³.

What the evidence does *not* yet settle is whether GLP-1 drugs have any bone effect beyond the weight loss they cause. GLP-1 receptors are present in bone-relevant tissue, and reviews of the emerging skeletal data describe the direct effect on bone as still uncertain — plausibly neutral or even protective in some models, but not established in humans⁴. The honest reading: the well-documented risk is the weight-loss-associated bone loss³, and the drug-specific bone signal remains an open question⁴.

Why this lands harder for women

Two facts stack here. First, the trials that quantified lean-mass loss were majority-female, so these proportions describe women directly¹². Second, women lose weight during exactly the life stages when bone is already vulnerable — the perimenopausal and postmenopausal decline in estrogen accelerates bone turnover, which is why our guide to GLP-1s through perimenopause and menopause treats bone as a first-order concern rather than a footnote. Layering rapid weight loss³ on top of that transition is the scenario worth planning around.

The preservation strategy that actually has evidence behind it

The same 2026 review that quantified the problem also points to the solution. Lifestyle-plus-resistance-training produced the most favorable body-composition profile of any approach studied, with lean-mass loss falling to about 17.5% of weight lost — the lowest of all groups analyzed¹. The authors' explicit conclusion is that muscle can be significantly preserved by integrating resistance training, adequate protein intake, and body-composition monitoring into a weight-loss program¹.

Translated into practice, that means: strength-train through the weight-loss phase rather than waiting until after; prioritize protein at every meal; and, where bone risk is a real concern, ask about baseline and follow-up measurement rather than assuming. A clinician-led program is better positioned to build that in than an app that only ships the medication — the kind of clinical depth our Metabolic-Fit Score methodology rewards, and one reason clinician-led options such as CoreAge Rx sit near the top of our ranking of GLP-1 providers for women. This article is educational only and not medical advice; decisions about GLP-1 treatment, bone testing, and exercise belong with a clinician who knows your history.